Saturday 17 October 2026 Export ALLO’s income statement to Excel — free account

Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $22,000.00, down 76.8% from fiscal 2023. In the quarter to June 2026, revenue grew 20,990.9%, EPS grew 43.5% and free cash flow grew 17.7%, each against the same quarter a year earlier.

1.31 0.03 −2.24%

Follow ALLO

Alert me

Market cap: $463.0M
P/E: 0.0×
Fwd P/E: −2.2×
Dividend yield: —
F-score: 3/9
Altman Z: −3.73
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.62

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	—	1	6	4	1	—	—	—	1	—	—

Insider Ownership 21.62%

Capital & Financial Ratios $m

Market Cap 462.96

Revenue 4.71

Net Income (165.49)

Free Cash Flow (102.60)

Net Debt (332.60)

Current Ratio 10.72

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (2.23)

P/S ratio 91.58

P/B ratio 0.99

Past 5Y EPS Growth —

This Y EPS Growth 30.88%

Next Y EPS Growth (5.70%)

Next Y revenue growth (92.27%)

Next 5Y EPS Growth 13.94%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 21.20%

10-year low 10-year high

P/B against its own 10 years 21.22%

10-year low 10-year high

EV/Sales against its own 10 years 22.61%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	449	292	250	333
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	459	303	258	340

	2023	2024	2025	Q'26
Payables	6	5	4	6
ST’ Debt	—	—	—	—
Other	—	—	—	—
	37	36	33	32

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	(94.22%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(22.98%)	(24.02%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	5	—	—	—
’24	0	—	—	—	0
’23	0	0	0	0	0
’22	0	0	0	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(13)	(32)	—	—	—
’25	(53)	(39)	(30)	(28)	(149)
’24	(56)	(64)	(44)	(37)	(200)
’23	(67)	(62)	(56)	(54)	(238)
’22	(68)	(43)	(48)	(62)	(221)
’21	(49)	(41)	(49)	(45)	(185)
’20	(41)	(27)	(38)	(10)	(115)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(13)	(32)	—	—	—
’25	(53)	(39)	(30)	(28)	(150)
’24	(56)	(64)	(45)	(37)	(201)
’23	(68)	(62)	(56)	(54)	(239)
’22	(70)	(44)	(48)	(64)	(226)
’21	(56)	(52)	(52)	(46)	(206)
’20	(53)	(43)	(58)	(27)	(181)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.18)	(0.13)	—	—	—
’25	(0.28)	(0.23)	(0.19)	(0.17)	(0.87)
’24	(0.38)	(0.35)	(0.32)	(0.28)	(1.32)
’23	(0.68)	(0.53)	(0.37)	(0.51)	(2.09)
’22	(0.56)	(0.52)	(0.58)	(0.66)	(2.32)
’21	(0.25)	(0.53)	(0.57)	(0.54)	(1.34)
’20	(0.50)	(0.53)	(0.52)	(1.08)	(2.08)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	21.67	24.60	17.43	12.90	5.56	2.23	1.78	0.86	Analyst estimates 2026–2028 Powerpack
	High	—	—	35.55	33.80	55.00	39.12	17.49	8.44	5.78	3.78
People
People	Employees	—	—	122	206	265	310	361	233	229	152
	Revenue/emp, $m	—	—	0.00	0.00	0.00	0.37	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	114	0	0	0	—
	Gross margin, %	—	—	0.00	0.00	0.00	100.00	100.00	100.00	100.00	—
	EBT	—	0	(212)	(185)	(316)	(182)	(340)	(327)	(257)	(191)
	EBT margin, %	—	0.00	0.00	0.00	0.00	(159.57)	(218,214.10)	(344,489.47)	(1,168,850.00)	0.00
	Net income	—	0	(212)	(185)	(316)	(182)	(340)	(327)	(258)	(191)
	Depreciation	—	0	0	1	11	17	17	7	5	8
Per share, $
Per share, $	Revenue	—	0.00	0.00	0.00	0.00	0.84	0.00	0.00	0.00	0.00
	Earnings	—	—	(7.31)	(1.83)	(2.08)	(1.34)	(2.32)	(2.09)	(1.32)	(0.87)
	Cash flow	—	0.00	(1.54)	(1.36)	(0.96)	(1.36)	(1.54)	(1.51)	(1.03)	(0.68)
	Capex	—	0.00	(0.18)	(0.50)	(0.55)	(0.16)	(0.04)	(0.01)	0.00	0.00
	Free cash flow	—	0.00	(1.73)	(1.86)	(1.50)	(1.52)	(1.58)	(1.52)	(1.03)	(0.68)
	Book value	—	0.00	24.29	6.22	8.97	6.81	4.66	3.26	2.17	1.33
	Shares, m	—	118	29	101	120	136	143	157	195	221
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	0.00	0.00	0.00	0.00	—
	P/S	—	—	—	—	—	17.76	5,285.44	5,979.93	4,769.53	—
	P/B	—	—	—	—	—	2.19	1.24	1.11	0.98	—
	EV/Sales	—	—	—	—	—	13.75	1,969.28	1,256.80	1,407.74	—
	EV/FCF	—	—	—	—	—	(7.61)	(1.36)	(0.50)	(0.61)	—
Cash, $m
Cash, $m	Operating cash flow	—	0	(45)	(137)	(115)	(185)	(221)	(238)	(200)	(149)
	Capex	—	0	(5)	(51)	(66)	(21)	(5)	(2)	(1)	0
	Free cash flow	—	0	(50)	(188)	(181)	(206)	(226)	(239)	(201)	(150)
Balance, $m
Balance, $m	Working capital	—	0	439	511	751	423	475	422	268	225
	Total debt	—	—	34	51	54	73	101	—	—	—
	Net debt	—	—	(459)	(531)	(828)	(457)	(517)	(449)	(292)	(250)
	Shareholders’ equity	—	0	703	629	1,080	925	667	512	422	293
Returns, %
Returns, %	ROA	—	0.00	(54.66)	(24.75)	(32.52)	(15.98)	(36.36)	(44.70)	(43.24)	(39.58)
	ROIC	—	0.00	(49.44)	(128.19)	(64.12)	(24.07)	(140.22)	(322.39)	(131.65)	(309.04)
	ROE	—	0.00	(60.16)	(27.71)	(37.03)	(18.16)	(42.76)	(55.51)	(55.13)	(53.42)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2024 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NGNE Neurogene Inc.	$479.3M	— (loss-making)	— (loss-making)	—	n/m	−22.97% (below 0%: shrinking)	100.00%	0.00%	Compare
YDES YD Bio Limited	$477.5M	—	—	—	—	—	—	—	Compare
RGNX REGENXBIO Inc.	$472.7M	— (loss-making)	— (loss-making)	+405.73% (above 0%: growing)	n/m	−26.67% (below 0%: shrinking)	99.04%	27.09%	Compare
ARVN Arvinas, Inc.	$468.2M	53.6×	— (loss-making)	+1,014.73% (above 0%: growing)	n/m	+49.79% (above 0%: growing)	96.40%	65.72%	Compare
CBIO Crescent Biopharma, Inc.	$463.6M	— (loss-making)	— (loss-making)	+1,038,900.00% (above 0%: growing)	n/m	−7.04% (below 0%: shrinking)	100.00%	0.00%	Compare
ALLO Allogene Therapeutics, Inc.	$463.0M	— (loss-making)	— (loss-making)	+20,990.91% (above 0%: growing)	n/m	+17.73% (above 0%: growing)	100.00%	(1,011.21%)
ALT Altimmune, Inc.	$459.1M	— (loss-making)	— (loss-making)	+520.00% (above 0%: growing)	n/m	−25.27% (below 0%: shrinking)	100.00%	0.00%	Compare
AUTL Autolus Therapeutics PLC Sponsored ADR	$457.8M	— (loss-making)	— (loss-making)	+118.37% (above 0%: growing)	n/m	+67.55% (above 0%: growing)	55.20%	(95.95%)	Compare
OCS Oculis Holding AG	$456.8M	— (loss-making)	— (loss-making)	+23.96% (above 0%: growing)	n/m	−10.40% (below 0%: shrinking)	100.00%	(7,603.42%)	Compare
Median of peers	$465.9M	—	—	+462.87%	—	−10.40%	100.00%	0.00%

All 614 Biotechnology stocks →

Allogene Therapeutics, Inc. (ALLO) key facts

Concern: Allogene Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $22,000.00, down 76.8% from fiscal 2023.
Allogene Therapeutics, Inc. (ALLO) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ALLO traded at $1.31, a market capitalization of $463.0 million.
Return on equity was −53.4% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −3.73 (distress zone) for fiscal 2024.

Source: company filings (standardised) and stockrow calculations.